NICE recommends removal of two drugs from CDF

The U.K.'s NICE issued preliminary draft guidances recommending the removal of two drugs from coverage by the country's Cancer Drugs Fund (CDF) for specific indications.

NICE said Afinitor from Novartis AG (NYSE:NVS; SIX:NOVN) "did not have plausible potential to be cost effective," even when offered an undisclosed discount under a patient access scheme, in combination with exemestane to treat postmenopausal women with hormone receptor-positive, HER2-negative breast cancer that has progressed after treatment with a non-steroidal aromatase inhibitor. ...